Highlights Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 18/06/2025 BST			5-day change	1st Jan Change
8.398 ^USD	+0.81%		-1.09%	-63.13%

05-22	Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	CI
05-22	Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study	RE

Highlights

Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	05-22	CI
Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study	05-22	MT
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study	05-14	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-13	CI
Quoin Pharmaceuticals Regains Compliance With Nasdaq	04-30	RE
Quoin Pharmaceuticals Ltd. Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of A Second Pediatric Patient	04-02	CI
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases	03-25	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	03-13	CI
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications	03-04	CI
Quoin Pharmaceuticals Ltd. Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study	02-27	CI
Quoin Pharmaceuticals Ltd. Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome	01-23	CI
Quoin Pharmaceuticals Ltd. Announces Positive Clinical Data from its Ongoing Pediatric Netherton Syndrome Study	01-16	CI
Quoin Pharmaceuticals Ltd. Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study	01-06	CI
Quoin Pharmaceuticals Prices $6.8 Million Equity Offering -- Shares Fall	12-20	MT
Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study	12-19	CI
Quoin Pharmaceuticals, Ltd. Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies	12-18	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-08	CI
Quoin Pharmaceuticals Seeks M&A Opportunities	11-06	CI
Quoin Pharmaceuticals Ltd. Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient	11-05	CI
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome	22/10/24	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08/08/24	CI
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome	06/08/24	CI
Quoin Pharmaceuticals, Ltd. Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome	27/06/24	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05/24	CI
Quoin Pharmaceuticals Seeks M&A Opportunities	14/03/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Highlights

Filters